Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes

Vaccine

Volumn 27, Issue 46, 2009, Pages 6444-6453

  Ramanathan, Mathura P ^d   Kuo, Yuan Chia ^a   Selling, Bernard H ^b   Li, Qianjun ^c   Sardesai, Niranjan Y ^d   Kim, J Joseph ^d   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Impact Biologicals Inc   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d VGX Pharmaceuticals Inc   (United States)

Author keywords

Dengue hemorrhagic fever; Dengue virus; Neutralizing antibodies; Tetravalent immunity

Indexed keywords

DENGUE VACCINE; DENGUE VACCINE 1 DIII; DENGUE VACCINE 2 DIII; DENGUE VACCINE 3 DIII; DENGUE VACCINE 4 DIII; DENGUE VACCINE UNIVERSAL DIII; DNA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CULTURE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DENGUE VIRUS; DNA IMMUNIZATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEROTYPE; STATISTICAL ANALYSIS; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL LINE; CROSS PROTECTION; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; GENETIC VECTORS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 70350055036     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.061     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention (CDC) DoV-bID-DF. [cited]; available from: http://cdc.gov/ncidod/dvbid/dengue.
2. Halstead S.B. Pathogenesis of Dengue: challenges to molecular biology. Science 239 (1988) 476-481
3. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 2 (2002) 100-103
4. Lindenbach B.R., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology (2001), Lippincott Williams & Wilkins, Philadelphia 991-1042
5. Rey F.A., Heinz F.X., Mandl C.W., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 (1995) 291-298
6. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells. J Virol 75 16 (2001) 7769-7773
7. Lin C.-W., and Wu S.-C. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol 77 4 (2003) 2600-2606
8. Mandl C.W., Allison S.L., Holzmann H., Meixner T., and Heinz F. Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol 74 20 (2000) 9601-9609
9. Allison S.L., Schalich J., Stiasny K., Mandl C.W., and Heinz F.X. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75 9 (2001) 4268-4275
10. Chu Y.-K., Ali G.D., Jia F., Li Q., Kelvin D., Couch R.C., et al. The SARS-CoV ferret model in an infection-challenge study. Virology 374 1 (2008) 151-163
11. Yang J.S., Kim J.J., Hwang D., Choo A.Y., Dang K., Maguire H., et al. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 184 7 (2001) 809-816
12. Yang J.S., Ramanathan M.P., Muthumani K., Choo A.Y., Jin S.H., Yu Q.C., et al. Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis 8 12 (2002) 1379-1384
13. Kutzler M.A., Robinson T.M., Chattergoon M.A., Choo D.K., Choo A.Y., Choe P.Y., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175 1 (2005) 112-123
14. Ramanathan M.P., Chambers J.A., Taylor J., Korber B.T., Lee M.D., Nalca A., et al. Expression and evolutionary analysis of West Nile virus (Merion strain). J Neurovirol 11 (2005) 544-556
15. Hirao L.A., Wu L., Khan A.S., Satishchandran A., Draghia-Akli R., and Weiner D.B. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26 3 (2008) 440-448
16. Hawkes R.A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 42 (1964) 465-482
17. Halstead S.B. Immune enhancement of viral infection. Prog Allergy 31 (1982) 301-364
18. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 6 Suppl (2003) 48-60
19. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24 9 (2006) 1238-1241
20. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 6 Suppl (2003) 24-31
21. Bray M., Men R., and Lai C.J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 70 6 (1996) 4162-4166
22. Chambers T.J., Liang Y., Droll D.A., Schlesinger J.J., Davidson A.D., Wright P.J., et al. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol 77 6 (2003) 3655-3668
23. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77 21 (2003) 11436-11447
24. Jaiswal S., Khanna N., and Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 77 23 (2003) 12907-12913
25. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11 2 (2004) 351-357
26. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 15 5 (1997) 547-552
27. Konishi E., Kosugi S., and Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 12 (2006) 2200-2207
28. Konishi E., Yamaoka M., Kurane I., and Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18 11-12 (2000) 1133-1139
29. Raviprakash K., Kochel T.J., Ewing D., Simmons M., Phillips I., Hayes C.G., et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18 22 (2000) 2426-2434
30. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simmons M., Phillips I., et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81 Pt 7 (2000) 1659-1667